Geron planning follow-on

Geron Corp. (NASDAQ:GERN) proposed a follow-on late Wednesday underwritten by BofA Merrill Lynch; Stifel; Lazard; Piper Jaffray; and MLV. This half, Geron plans to start a Phase II trial of imetelstat ( GRN163L) in patients with myelofibrosis (MF). Last year, data from an investigator-sponsored, open-label pilot trial showed imetelstat -- an oligonucleotide that competitively inhibits telomerase activity -- led to an overall response rate (ORR) of 44% in MF patients (see BioCentury Extra, Nov. 7, 2013). ...